| Literature DB >> 34926034 |
Anima Ferdous1, M Monir Hossain1, Manifa Afrin2.
Abstract
Severe dengue with the multisystem inflammatory syndrome in children (MIS-C) can be difficult to diagnose as both diseases have similar symptoms and laboratory findings. Bangladesh is currently facing a double burden of severe dengue and SARS-CoV-2 infection. Co-infection with these viruses can result in severe morbidity. Worldwide this co-infection is rare. However, we present five cases of severe dengue with possible MIS-C due to SARS-CoV-2 infection in children. All the children presented with shock with variable degrees of plasma leakage. Mucocutaneous and gastrointestinal involvement were common. All tested positive for dengue nonstructural protein 1 antigen on the second to the third day of fever and tested positive for anti-SARS-CoV-2 IgG by enzyme-linked immunosorbent assay. Echocardiographic evaluation in all patients showed coronary arterial abnormalities. Cardiac enzymes were abnormal, and there were raised inflammatory markers and abnormal coagulation profiles. One patient had neurological involvement and needed mechanical ventilatory support. All cases were successfully managed according to dengue shock syndrome guidelines and required intravenous immunoglobulin with prednisolone, aspirin, and in some cases, enoxaparin for the management of coronary arterial involvements, which is not a documented feature for severe dengue infection, but typically found in MIS-C due to SARS-CoV-2 infection or Kawasaki disease. This case series aims to describe the possibility of co-infection of severe dengue with MIS-C due to SARS-CoV-2 infection in a dengue-endemic region during the coronavirus disease 2019 (COVID-19) pandemic, and alternatively, dengue virus as an unusual etiology for Kawasaki disease was also entertained. Severe dengue in endemic regions can coexist with COVID-19 during an outbreak, making it hard to diagnose. It can be fatal without early, appropriate management.Entities:
Keywords: covid 19; dengue with mis-c co-infection; mis-c in children; sars-cov-2 (severe acute respiratory syndrome coronavirus -2); severe dengue
Year: 2021 PMID: 34926034 PMCID: PMC8654339 DOI: 10.7759/cureus.19516
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Investigation profile of cases
NT-pro = N-terminal-pro hormone
| Investigations | Reference range | Case 1 | Case 2 | Case 3 | Case 4 | Case 5 |
| Dengue nonstructural protein 1 antigen (NS1 Ag) | + | + | + | + | + | |
| Anti-SARS-CoV-2 IgG (ELISA) | + | + | + | + | + | |
| Complete blood count | ||||||
| Hemoglobin (g/dl) | Male, 12-17; female, 11.5-15.5 | 10 | 14 | 9.6 | 9.1 | 15.4 |
| Hematocrit (%) | Male, 40-52; female, 36-48 | 31 | 42 | 29 | 28.2 | 44.4 |
| Total WBC (109/L) | 4-11 | 4.9 | 6.98 | 5 | 4.6 | 10.6 |
| Neutrophils (%) | 40-75 | 56 | 77 | 17 | 45 | 34 |
| Platelet count (109/L) | 150- 450 | 55 | 25 | 32 | 32 | 42 |
| C-reactive protein (mg/dL) | 0.01-0.30 | 3.16 | 5.00 | 7.66 | 3.02 | 1.21 |
| Serum procalcitonin (ng/mL) | <2.0 | 0.87 | 0.1 | 5.20 | 0.47 | 1.56 |
| Serum albumin (g/dl) | 3.4-5.0 | 4.15 | 3.17 | 2.75 | 2.17 | 1.8 |
| Serum calcium (mg/dl) | 8.20- 10.20 | 9.3 | 7.8 | 7.9 | 6.00 | 6.60 |
| Alanine transferase (ALT) (U/L) | <40 | 30 | 97 | 35 | 30 | 578 |
| Aspartate aminotransferase (AST) (U/L) | <37 | 70 | 168 | 92 | 78 | 180 |
| Prothrombin time (PT) (sec) | Control- 12 | 14 | 14 | 12 | 16 | 17 |
| Activated partial thromboplastin time (APTT) (sec) | Control- 28 | 72 | 36 | 34 | 55 | 53 |
| Blood urea (mg/dl) | 10-40 | 30 | 12 | 10 | 10 | 41 |
| Serum creatinine (mg/dl) | 0.2-0.7 | 0.58 | 0.78 | 0.42 | 0.67 | 0.84 |
| Serum ferritin (ng/ml) | 7-140 | Before treatment: >2000 After treatment: 432 | Before treatment: >2000 | Before treatment: 595 | Before treatment: 2000 After treatment: 950 | Before treatment: >2000 After Treatment: 980 |
| D-dimer (mg/L) | <0.5 | Before treatment: >5 | Before treatment: >5 After treatment: 1.35 | Before treatment: >5 After treatment: 2.7 | Before Treatment: 5 After treatment: 0.37 | Before Treatment: >5 After treatment: 2.3 |
| NT-pro-B-type natriuretic peptide (pg/ml) | <125 | Before treatment: 8953 After treatment: 2058 | Before treatment: 1550 After treatment: 383 | Before treatment: 3730 After treatment: 2031 | Before treatment: 390 After treatment: 140 | Before treatment: 9432 After Treatment: 5022 |
| Serum troponin I (ng/ml) | 0.00-0.056 | Before treatment: 1.844 After treatment: 0.430 | 0.00 | Before treatment: 0.579 After treatment: 0.019 | Before treatment: 0.017 After treatment: 0.00 | Before treatment: 0.485 After treatment: 0.30 |
Figure 1An image of the trunk of Case 1
The blue arrow shows erythematous maculopapular rash on the trunk
Figure 2Echocardiogram of Case 1
The image shows dilated coronaries with loss of distal tapering and mild left ventricular dysfunction (ejection fraction, 52%)
Figure 3Chest X-ray of Case 2
Blue arrows show bilateral pleural effusion and yellow arrows show bilateral pneumonitis
Figure 4Echocardiography of Case 3
Echocardiography revealed prominent coronaries, mildly dilated left ventricle, mild left ventricular dysfunction (ejection fraction, 57%)
Figure 5An image of eyes of Case 3
Yellow arrows show bilateral conjunctival congestion
Figure 6Chest X-ray of Case 4 during mechanical ventilation
Yellow arrows show bilateral patchy opacities with consolidation (red arrow) and pleural effusion (blue arrow)
Figure 7Echocardiogram of Case 4
The echocardiogram revealed dilated coronaries with loss of distal tapering, mild left ventricular dysfunction (ejection fraction, 51%)
Figure 8Chest X-ray of Case 5
The blue arrow shows pleural effusion and the yellow arrows show bilateral patchy opacities